Skip to main content

Month: September 2023

Acorn Hosts Annual Stockholder Meeting and Management Q&A in Person and via Zoom on Tuesday, September 12th at 1pm ET

BALTIMORE and WILMINGTON, Del., Sept. 06, 2023 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN), a provider of remote monitoring and control solutions for stand-by power generators, gas pipelines, air compressors and other critical industrial assets, will hold its 2023 Annual Meeting of Stockholders at 1:00 PM ET on Tuesday, September 12, 2023 at 2800 Quarry Lake Drive, Suite 130, Baltimore, Maryland 21209. The meeting will also be accessible via Zoom for investors who register in advance by contacting Acorn’s Assistant Secretary by email at AcornMeeting@gmail.com. Annual Meeting Zoom Link: https://us02web.zoom.us/j/84545768072Telephone number: 1-646-558-8656 Meeting ID: 845 4576 8072 Registered participants will be admitted from the Zoom waiting room into the meeting at approximately 12:55 PM ET. On the day of the meeting,...

Continue reading

Gryphon Investors-Backed Meazure Learning Acquires Examity from Great Hill Partners

Online Proctoring Solutions Company Expands Meazure’s Operations, Technologies, and Services SAN FRANCISCO, Sept. 06, 2023 (GLOBE NEWSWIRE) — Meazure Learning, a leading full-service provider of test development and delivery solutions for higher education and professional testing, announced today it has acquired Examity, a leader in online proctoring for educators, certifying bodies, employers, and other assessment providers, from Great Hill Partners. Meazure Learning is a portfolio company of middle-market private equity firm Gryphon Investors. Great Hill will retain a minority position in Meazure moving forward, joining Gryphon, Eastside Partners, and members of the management team as stakeholders in the combined entity. Financial terms of the transaction were not disclosed. Founded in 2013, Examity partners with hundreds of...

Continue reading

Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook

Total revenue and other income nearly doubled (€2,4 million, +95%) R&D progress across the board, including initiation of the 4-arm Phase 2 clinical trial for AlenuraTM, targeting IC/BPS, a condition affecting at least 6 million U.S. patients PDUFA goal date for Maxigesic® IV set for 17 October 2023 by the U.S. FDA1 Evaluating external product candidates & advancing internal projects to reach 30 key assets before 2025 Multiple NDA2 submissions expected within the next 18 months Analyzing different go-to-market strategies for commercial launch of a range of cardiovascular product candidates in the U.S. healthcare market Net cash position of €39,2 million, sufficiently capitalized for all expected R&D expenditures related to the current product candidates3Webcast 7 September at 3PM CET / 2PM GMT / 10AM EST (register here) Liège,...

Continue reading

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ label Litigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTAB)MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company), announced today that United Therapeutics Corporation (UTHR) filed a patent infringement action under the Hatch-Waxman Act in the U.S. District Court for the District of Delaware (District Court) asserting infringement of U.S. patent No. 10,716,793 (‘793 patent) in response to Liquidia’s amendment to add the PH-ILD indication to the tentatively approved New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder. The ‘793 patent was previously...

Continue reading

DraftKings Announces Jason Park’s Participation in Upcoming Event

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced that Jason Park, the Company’s Chief Financial Officer, will participate in the following event:The Bank of America 2023 Gaming and Lodging Conference. The fireside chat is scheduled for 3:20PM ET on September 7, 2023.Registration and the live audio portion of the Bank of America 2023 Gaming and Lodging Conference can be accessed at the conference website or at DraftKings’ Investor Relations website. About DraftKings DraftKings Inc. is a digital sports entertainment and gaming company created to fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming and digital media. Headquartered in Boston, and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman,...

Continue reading

Host Hotels & Resorts Provides Update on Maui Wildfires and Other Recent Weather Events

BETHESDA, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) — Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, today provided an update regarding the impact of the Maui wildfires and other recent weather events on its hotels and the communities where they operate. As the largest hotel real estate owner on Maui with a presence for over 20 years, Host Hotels & Resorts shares a deep connection to the island’s people and culture. Lahaina has long been revered as a sacred place and home to some of the island’s most precious historical and cultural assets. The August wildfires touched everyone on the island and the Company’s hotels are partnering together to support the safety and wellbeing of the Maui community. The Company’s hotels are providing food and shelter for...

Continue reading

Hepion Pharmaceuticals Announces Management Changes

EDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, announced that Stephen Harrison, M.D., has been appointed as Consultant Medical Director. Dr. Harrison, the current Chairman of Hepion’s Scientific Advisory Board (“SAB”), succeeds Todd Hobbs, M.D., who has provided notice to the Company of his resignation as Chief Medical Officer, effective September 29, 2023. Dr. Harrison previously served as Hepion’s Consultant Medical Director from October 2019 until February 2021. He is currently a Visiting Professor of Hepatology at the Radcliffe...

Continue reading

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay on that site following the event. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative...

Continue reading

Streamline Health® To Report Second Quarter 2023 Financial Performance and Provide Corporate Update

Atlanta, GA, Sept. 06, 2023 (GLOBE NEWSWIRE) — Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced that it will release its financial results for the three month period ended July 31, 2023 on Wednesday September 13, 2023 after the close of the financial markets. The Company will conduct a conference call on Thursday, September 14, 2023, at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291. Following the conference call, management will host 1×1 meetings at the Lake Street Capital Markets 7th...

Continue reading

Transcontinental Inc. Announces Results for the Third Quarter of Fiscal 2023

HighlightsLower volume in the Packaging and Printing Sectors, partially offset by the positive impact of actions implemented to adjust our cost structure. Revenues of $706.7 million for the quarter ended July 30, 2023; operating earnings of $39.2 million; and net earnings attributable to shareholders of the Corporation of $20.9 million ($0.24 per share). Adjusted operating earnings before depreciation and amortization(1) of $107.9 million for the quarter ended July 30, 2023; adjusted operating earnings(1) of $70.2 million; and adjusted net earnings attributable to shareholders of the Corporation(1) of $44.0 million ($0.51 per share). On August 22, 2023, announced a major investment to accelerate the commercialization of innovative recyclable flexible packaging.(1) Please refer to the section entitled “Non-IFRS Financial Measures”...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.